Orencia Sales Data

Rank 65 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Orencia U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 65 (1) 1.65% 0.31%
Q3 2013 64 -0.26% -4.39%
Q2 2013 64 (10) 9.63% 5.23%
Q1 2013 74 2.68% -0.91%
Q4 2012 74 (2) 3.89% -2.09%
Q3 2012 76 (6) 6.17% 1.52%
Q2 2012 82 (15) 11.23% 5.10%
Q1 2012 97 ()

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
May 15, 2012U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA (abatacept)
Hide
(web1)